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Objective:  To  determine  presenting  features,  management  and  prognosis  in  extranodal  non-Hodgkin
lymphoma  of the  sinonasal  tract.
Material  and  methods:  A retrospective  study  between  2004  and  2013  in  the  University  Hospital  Center  of
Nantes  (France)  recruited  patients  with  lymphoma  discovered  by  sinonasal  involvement.  Epidemiologic,
diagnostic,  clinical  and  prognostic  criteria  were  analyzed,  with  survival  studied  on the Kaplan-Meier
estimator  and  Log-rank  test.
Results:  Twenty-two  patients  were  included:  14  male,  7 female,  with a  mean  age  of 65 years  at  diagnosis.
All  had  non-Hodgkin  lymphoma,  with  strong  predominance  of  diffuse  large  B-cell  lymphoma  (77%).
Seven  patients  had  risk  factors  for lymphoma  (infection  by  HIV,  EBV  or chronic  lymphocytic  leukemia).
A  majority  (68%)  had  advanced  tumor  at diagnosis  (stage  IV  on  the Ann  Arbor  classiﬁcation).  Most  were
located  in  the  craniofacial  bones  (68%),  mainly  involving  the  maxillary  or ethmoidal  sinuses.  The  most
frequent  presenting  symptoms  were  unilateral  nasal  obstruction,  mucopurulent  rhinorrhea,  recurrent
epistaxis  or  diplopia.  Treatment  consisted  in  chemotherapy,  in some  cases  associated  to  radiotherapy.
Overall  survival  was  82% at 12  months  and  73% at 36  months.  Recurrence-free  survival  was  76% at 12
months  and  64%  at 36  months.
Conclusion:  Lymphoma  is an  aggressive  pathology;  revelation  by sinonasal  involvement  is rare.  Recom-
mended  treatment  is  chemotherapy,  possibly  associated  to radiotherapy.  Prognosis  depends  on  histologic
type,  Ann  Arbor stage  at diagnosis  and the  therapeutic  options  available  for the  individual  patient.
©  2015  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
The head and neck region accounts for more than one-third of
xtranodal lymphomas. The nasal cavities and the sinuses, how-
ver, are rarely involved in Caucasian populations, representing
nly 0.2–2% of head and neck lymphomas [1].
Conversely, lymphoma accounts for 11% of sinonasal cancers
2], and thus come to be regularly encountered by ENT physicians,
ho should be ready to suspect this diagnosis in case of craniofacial
one tumor.
The main diagnostic problem is the lack of speciﬁc clinical signs,
ften leading to late consultation and thus diagnosis at an advanced
tage.
∗ Corresponding author.
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879-7296/© 2015 Elsevier Masson SAS. All rights reserved.Initial management should therefore be codiﬁed to avoid delay
in treatment, as earlier diagnosis improves prognosis in this aggres-
sive pathology. Lymphoma treatment is mainly medical, thus
requiring close teamwork between surgeon and hematologist.
A retrospective study recruited all cases of sinonasal lymphoma
diagnosed and/or treated between 2004 and 2013 in the University
Hospital Center of Nantes (France). The objective was to determine
clinical, pathologic, radiologic and prognostic characteristics, with
a view to optimizing management.
2. Materials and methods
A retrospective study recruited patients diagnosed with lym-
phoma of the sinuses or nasal cavities in the University Hospital
Center of Nantes between 2004 and 2013.
Patients were identiﬁed from the pathology department
database. The inclusion criterion was diagnosis of lymphoma
initially revealed by facial sinus or nasal cavity involvement.
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Table  1
Ann Arbor staging.
Stage Deﬁnition
I Disease in single lymph node or lymph node region
II  Disease in two or more lymph node regions on same side
of diaphragm
III  Disease in lymph node regions on both sides of the
diaphragm
IV Disease is widespread, by hematogenic route, including
multiple involvement at one or more extranodal sites
E  Extranodal invasion by contiguity
X
B
Large tumor (diameter > 10 cm mediastinal-thoracic
ratio > 1/3)
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Table 2
Signs on initial examination.
Initial clinical signs Patients (n) %
Endonasal mass 16 73
Nasal obstruction 8 36
Diplopia 6 27
Rhinorrhea 5 23
Epistaxis 5 23
Exophthalmus 5 23
Pain  4 18
Endo-oral swelling 4 18
Cranial nerve deﬁcit 2 9
Epiphora 2 9
Adenopathy 1 4.5With symptoms (weight-loss > 10%, sweats, fever)
ymphomas that had invaded the nasal cavities or sinuses but
ith rhinopharyngeal, oropharyngeal or cutaneous origin were
xcluded, as were cases of sinus recurrence of nodal or extranodal
ymphoma or sinonasal locations of other hemopathic malignan-
ies.
All patients underwent ENT consultation for exploration of one
r more chronic clinical sinonasal signs.
Age at diagnosis, presenting symptomatology, time from
ymptom onset to treatment initiation, risk factors, paraclinical
ssessment and treatment modalities were analyzed.
All biopsies were fresh samples studied under photon
icroscopy to analyze tumor architecture.
Immunohistochemistry determined phenotype (B or T), anti-
ody expression (CD3, CD5, CD10, CD 20, Bcl2 and anti C-Myc) and
roliferation index.
Paraclinical assessment enabled staging on the Ann Arbor clas-
iﬁcation (Table 1).
IPI (International Prognostic Index) was calculated, based on
 factors: age (over 60 years), clinical stage (III/IV), performance
ndex (equal to or greater than 2), LDH elevation, and involvement
f 2 or more extranodal levels.
Files were discussed in multidisciplinary hematology team
eeting to determine the appropriate treatment strategy.
Various factors were analyzed to determine their impact on
urvival: age, gender, Ann Arbor stage, IPI score, histologic type,
inus involvement, localized or diffuse form, and treatment imple-
ented.
Survival was calculated following Kaplan-Meier and compar-
sons performed on Log-rank test.
. Results
Between 2004 and 2013 in the Nantes University Hospital, 22
atients had histologic diagnosis of lymphoma of the nasal cavities
nd/or sinuses.
The male:female sex ratio was 2:1 (14 male, 8 female). Mean
ge at diagnosis was 59 years (range, 36–95 years).
Seven patients showed lymphoma risk factors: EBV or HIV infec-
ion, history of lymphopathy.
Presenting symptoms were poorly speciﬁc, with classic
inonasal functional signs: unilateral nasal obstruction, mucopuru-
ent rhinorrhea, epistaxis and anosmia. However, these signs were
ystematically unilateral. A considerable number of patients (16 out
f 22) showed non-rhinologic signs: diplopia (27%), exophthalmus
18%), endo-oral swelling (18%) or cranial nerve palsy (9%). Only
 patient showed cervical adenopathy. Clinical examination found
asal cavity tumor syndrome in 16 patients (Table 2).Depending on the patient, all sinuses showed involvement, with
 clear predominance for the maxillary sinus (50%), followed by the
thmoidal sinus (23%), nasal cavities (18%) and sphenoidal sinus(9%). There was  no frontal sinus involvement. Ten patients (45%)
showed left-side and 12 (55%) right-side involvement.
Mean interval between symptom onset and diagnosis, reliably
determined in 19 patients, was  4 months (range, 15 days to 27
months).
Craniofacial imaging was systematic: CT (14 patients) and/or
IRM (8 patients), with remote extension assessment on cervico-
thoraco-abdomino-pelvic CT; 10 patients had complementary
PET-CT. 15 patients showed localized craniofacial involvement.
Imaging indicated a homogeneous craniofacial tumoral mass,
sometimes with spontaneous tumoral uptake (5 patients) or
bone lysis (17 patients) (Fig. 1). Seven patients underwent
osteomedullary biopsy; none showed medullary involvement.
Lumbar ﬁne-needle aspiration cytology, performed in 3 patients,
was normal.
The lymphomas were all non-Hodgkin forms: 17 diffuse large
B-cell (77%), 3 nasal NK/T and 2 plasmablastic.
Ann-Arbor staging (Table 1) found 2 stage IE tumors, 3 IIE, 1 IIIE
and 16 IV.
A total of 15 patients had localized craniofacial tumor, although
11 of these were stage IV due to bone lysis (9 cases) or orbital
inﬁltration (2 cases).
General signs (> 10% weight loss, sweats, fever) were rare, found
in only 4 cases; LDH elevation concerned only 3 patients.
Treatment strategy was determined in multidisciplinary hema-
tology team meeting. Three patients with localized craniofacial
involvement received primary exclusive radiotherapy. Sixteen
received primary exclusive chemotherapy (usually cyclophos-
phamide, doxorubicin, vincristine and prednisone or CHOP).
Eight patients showed incomplete response: 4 underwent
salvage chemotherapy and bone marrow autograft, and 7 comple-
mentary craniofacial radiotherapy. One patient underwent surgical
tumor resection, due to biopsy and multiple frozen section biopsies
indicating malignancy, without further detail as to histologic type;
lymphoma was diagnosed on deﬁnitive pathology examination.
Follow-up was  clinical, biological and radiological, for a mean 30
months (range, 2–72 months). Two  patients were lost to follow-up,
and 1 was  not followed up due to age (95 years).
Overall survival was 82% at 12 months and 73% at 36 months.
Recurrence-free survival was 76% at 12 months and 64% at 36
months (Fig. 2: (A) overall survival, (B) recurrence-free survival).
Several factors tended to show positive association with sur-
vival: age (Fig. 3), male gender, IPI score < 2, histologic type diffuse
large B-cell, and sinus involvement; the differences, however, were
non-signiﬁcant.
Survival in localized tumor (stage IE, or IV with exclusively cra-
niofacial location) was  88% at 12 months and 80% at 36 months.
There was  no signiﬁcant difference in overall survival between
localized (IE) and advanced stages (IIE, IIIE and IV), (P = 0.9) (Fig. 3:
overall survival according to (A) age and (B) stage).
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Fig. 1. Contrast-enhanced facial bone CT-scan, coronal slice showing (A) bone lysis
of  the skull base and medial orbital wall by ethmoidal-maxillary tumor: Ann Arbor
stage IV lymphoma; (B) malignant right maxillary sinus tumor: diffuse large B-cell
l
4
l
o
r
a
l
p
i
l
p
1
t
t
l
p
panied by signs due to tumor volume (diplopia, exophthalmus,
endo-oral swelling, neurologic deﬁcit); unilateral presentation
and treatment failure indicate complementary examination [1,12].ymphoma.
. Discussion
The head and neck region is a frequent site of tumoral invasion in
ymphoma. Cervical lymph-node involvement is found in 39–72%
f cases [3,4]. Extranodal involvement mainly concerns Waldeyer’s
ing [5]. Sinonasal involvement is rarer in Caucasian populations,
t 0.2–5% of cases [1,6], unlike in Asian and South American popu-
ations, where it holds second place after digestive locations [6].
Histologic types are exclusively non-Hodgkin malignant lym-
homa [6]. In Caucasian populations, diffuse large B-cell lymphoma
s the prevalent type, while in Asia and South America nasal NK/T
ymphoma predominates [1,6–11]. This pattern was  found in the
resent series, with 77% diffuse large B-cell lymphoma and only
3% nasal NK/T lymphoma. Nasal NK/T lymphoma mainly involves
he nasal cavities, whereas diffuse large B-cell lymphoma involves
he sinuses [11,12].The association of Epstein-Barr virus (EBV) infection with NK/T
ymphoma is well-established [8,13], and was systematic in the
resent series.Fig. 2. Curves for (A) overall and (B) recurrence-free survival.
Two  of the present series had human immune-deﬁciency virus
(HIV) infection, and showed plasmablastic lymphoma. This is a rare
hemopathy and a variant of diffuse large B-cell lymphoma, found
almost exclusively in association with HIV infection [14]. Sinus
involvement is exceptional, plasmablastic lymphoma being mainly
revealed by oral cavity involvement [14].
Mean age at diagnosis ranges from 45 to 75 years, with clear
male predominance [1,9–11,15,16], as in the present series with a
2:1 ratio and a mean age of 59 years.
Revelation is mainly by rhinologic signs (nasal obstruction,
mucopurulent rhinorrhea, iterative epistaxis), sometimes accom-Fig. 3. Overall survival according to (A) age and (B) stage.
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oreover, endonasal examination, which can be performed in con-
ultation, often ﬁnds a tumoral process (73%, in the present series).
ervical adenopathy was unusual (1 case), and has nothing speciﬁc
o lymphoma [17]. The maxillary sinus is the most frequent location
1,11,16,18], as in the present series (50% of patients).
Morphologic assessment is the same as for other lymphomas,
omprising contrast-enhanced CT-scan, completed by PET-CT [19].
Craniofacial imaging usually found homogeneous unilateral
pacity, sometimes with spontaneous uptake (5 patients), and
requent bone lysis (17 patients). This aspect is not speciﬁc to lym-
homa, but malignancy should be suspected in case of association
f several radiologic signs: bone lysis, unilateral and/or heteroge-
eous opacity and heterogeneous contrast-medium uptake [2].
Osteomedullary biopsy is recommended in all forms of non-
odgkin lymphoma, to explore for medullary involvement, with
umbar ﬁne-needle aspiration cytology in head and neck locations
r in case of neurologic signs [19].
Treatment is exclusively medical, based on chemotherapy
nd/or external radiotherapy [20]. Exclusive radiotherapy is a treat-
ent of choice for localized forms with small tumor size (< 5 cm), as
ecommended by Quirashi et al. [1]; moreover, in elderly patients
t has the advantage of lower toxicity. However, several studies
ave reported efﬁcacy for combined treatment in localized forms
ith large tumor volume [1,12,16]. Chemotherapy is the treat-
ent of choice in disseminated forms, the most usual protocol
eing CHOP. Some authors recommend systematic complementary
raniofacial radiotherapy, even in disseminated forms [9,11,16].
n the present series, primary treatment was mainly chemother-
py (16 patients), due to patients’ Ann Arbor stage. Radiotherapy
as implemented secondarily for incomplete craniofacial response
n 7 cases, achieving complete remission in 4. No survival gain
or combined treatment versus exclusive chemotherapy could be
emonstrated, for lack of power.
The classic major prognostic factors are Ann Arbor stage, IPI
core, histologic type and symptoms at diagnosis [9,16]. A trend
oward better survival could be seen for IPI score < 2 and diffuse
arge B-cell lymphoma (respectively 83% and 80% at 36 months),
ut did not prove signiﬁcant. As in the present series, Kanumuri
t al. [10] found no association between overall or recurrence-free
urvival and sinus involvement.
The present series included a high rate of advanced stages: 72%
tage IV and only 9% localized IE stages. Other series reported a
ajority of localized stages, with 46–76% IE. Despite the present
ate of IV stage lymphoma, 3-year overall and recurrence-free sur-
ival, at respectively 73% and 88%, were better than expected for
uch advanced disease; this may  have been due to the stage-IV
ases being mainly localized in the facial bones and graded stage
V due to bone lysis or orbital inﬁltration. Their staging was  thus
ebatable, as extralymphatic inﬁltration was by contiguity and not
ematogenic dissemination in 15 out of 16 cases. Logsdon et al.
emonstrated the limitations of Ann Arbor staging in sinus lym-
homa, comparing it with the AJCC 2007 TNM classiﬁcation, which
s the reference for craniofacial tumor: certain sinus lymphomas,
lthough staged T4, may  be IE according to the Ann Arbor classiﬁca-
ion; moreover, they reported 70% 5-year progression-free survival
n IE-T4 tumor, versus only 29% in stage IV and 80% in other IE
tages. In the present series, 3-year survival in localized craniofacial
umor was 80%, suggesting overstaging in 11 cases out of 15.
In conclusion, the present study, although biased by its ret-
ospective design, conﬁrmed that sinonasal lymphoma is a rare
athology, difﬁcult to diagnose as revealing signs may  mimic
[
[ogy, Head and Neck diseases 132 (2015) 271–274
simple rhinosinusitis. Persistence or aggravation of symptoms,
however, indicates at least one complete ENT examination, with
ﬂexible endoscopy. In case of unilateral nasal cavity lesion, fresh
biopsy should be performed to screen for lymphoma.
In Caucasian populations, the most frequent histologic type is
diffuse large-cell lymphoma, where prognosis is better than in the
nasal NK/T forms predominating in Asia and South America.
Prognosis depends on histologic type, Ann Arbor grade, and gen-
eral signs and IPI index at diagnosis. There is a risk of overstaging
on the Ann Arbor classiﬁcation, due to the frequency of bone or
visceral involvement (brain, orbit) in sinus locations.
Treatment is based on an association of radio- and chemother-
apy in most cases.
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